Shenzhen Hepalink Pharmaceutical Group Co (SZSE:002399) Ending Cash Position : ¥2,108 Mil (As of Mar. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Shenzhen Hepalink Pharmaceutical Group Co Ending Cash Position?

Shenzhen Hepalink Pharmaceutical Group Co's Ending Cash Position for the quarter that ended in Mar. 2024 was ¥2,108 Mil.

Shenzhen Hepalink Pharmaceutical Group Co's quarterly Ending Cash Position increased from Sep. 2023 (¥1,758 Mil) to Dec. 2023 (¥1,766 Mil) and increased from Dec. 2023 (¥1,766 Mil) to Mar. 2024 (¥2,108 Mil).

Shenzhen Hepalink Pharmaceutical Group Co's annual Ending Cash Position declined from Dec. 2021 (¥1,480 Mil) to Dec. 2022 (¥1,320 Mil) but then increased from Dec. 2022 (¥1,320 Mil) to Dec. 2023 (¥1,766 Mil).

Shenzhen Hepalink Pharmaceutical Group Co Ending Cash Position Historical Data

The historical data trend for Shenzhen Hepalink Pharmaceutical Group Co's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shenzhen Hepalink Pharmaceutical Group Co Ending Cash Position Chart

Shenzhen Hepalink Pharmaceutical Group Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

Get a 7-Day Free Trial

1,076.54

1,330.25

1,479.63

1,319.71

1,765.65

Shenzhen Hepalink Pharmaceutical Group Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Ending Cash Position	Get a 7-Day Free Trial															1,753.15	1,438.06	1,757.78	1,765.65	2,108.38

Shenzhen Hepalink Pharmaceutical Group Co Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Shenzhen Hepalink Pharmaceutical Group Co's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	1319.707	+	445.938
	=	1,766

Shenzhen Hepalink Pharmaceutical Group Co's Ending Cash Position for the quarter that ended in Mar. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	1765.645	+	342.739
	=	2,108

Shenzhen Hepalink Pharmaceutical Group Co Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Shenzhen Hepalink Pharmaceutical Group Co's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Shenzhen Hepalink Pharmaceutical Group Co (SZSE:002399) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shenzhen Hepalink Pharmaceutical Group Co Ltd (SZSE:002399) » Definitions » Ending Cash Position

Traded in Other Exchanges

09989:Hong Kong

Address

No. 21 Langshan Road, Songping Mountain, Guangdong Province, Nanshan District, Shenzhen, CHN, 518057

Website

https://www.hepalink.com

Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based company engaged in biopharmaceutical production, biopharmaceutical services, biopharmaceutical trading and biopharmaceutical research and development. The company distributes its products both in the domestic and overseas markets. The Group mainly operates three main business segments, including Finished dose pharmaceutical products business; Active pharmaceutical ingredients; CDMO business and Others. Geographical presence of company is in Hong Kong, United States of America, Europe, Mainland China and Other countries. Majority of the company's revenue comes from USA and Europe.

Executives

Zhang Ping	Director
Li Li	Director
Kong Yun	Executives
Li Tan	Directors, executives

Shenzhen Hepalink Pharmaceutical Group Co (SZSE:002399) Headlines

No Headlines